About US
Contact us
-
Hey, European countries--join forces to bring down drug prices, WHO suggestsYou want to reduce high prices for new meds, European countries? Here's a suggestion for you: Work together. According to a new study from the World Health Organization (WHO), it's becoming increasin2015/3/27
-
Dr. Reddy's shopping for deals up to $1B as it expands in injectable medsDr. Reddy's Laboratoriesis eyeing deals as big as $1 billion to build up its portfolio of higher-end products, including generic injectable drugs, and expand its footprint in emerging markets.2015/3/27
-
Amoun Pharma investors make another run at a $700M-plus saleIt's try, try again for Egypt-basedAmoun Pharmaceuticals. The drugmaker, among the largest in its home country, hired Goldman Sachs to look for potential buyers after previous efforts failed. AsBloom2015/3/26
-
Geriatrics experts call for halt to Low-T consumer adsA couple of geriatrics experts have joined the chorus of recommendations againsttestosteronetherapy. But they're going a step further. They say drugmakers' enthusiastic advertising--which happened to2015/3/26
-
Merck's Keytruda bests BMS' Yervoy in head-to-head melanoma trialAdvantage Merck ($MRK) in the melanoma immunotherapy race. The U.S.-based company says its PD-1 drugKeytrudamet its goals in a head-to-head study with Bristol-Myers Squibb's ($BMY)Yervoy(ipilimumab),2015/3/25
-
Which diseases are driving drug spending hikes? It's not just hep CIndustry watchers well know that U.S. drug spending is rising--a lot. And they also know that it's likely to continue over the next few years if some major changes don't occur. But which medical condi2015/3/25
-
With MenB vaccine Bexsero in hand, GSK aims for a price deal in EnglandNovartis ($NVS) may have spent 7 months negotiating fruitlessly with the U.K. government over the price of meningitis B vaccine Bexsero, but now that the product is in GlaxoSmithKline's ($GSK) hands,2015/3/24
-
Jury: Boy didn't prove J&J drug caused his breast growthJohnson & Johnson ($JNJ) won a split decision in Philadelphia court Friday, in the latestRisperdallawsuit to go to trial. A jury decided that J&J did fail to warn doctors that the antipsychoti2015/3/24
-
Hedge fund patent challenges are growing by the numbers, and drugmakers aren't happyGenerics makers aren't the only ones filing challenges to pharma patents anymore. Hedge funds are doing it, too, and it's got drugmakers on edge. The funds, taking advantage of rulesCongresscreated t2015/3/23
-
Biogen Alzheimer's drug reignites excitementThe success of Biogen Idec's ($BIIB) closely watched antibody targeting beta amyloid proteins inAlzheimer'sdisease is again bringing some excitement to a category that has defeated earlier enthusiasm2015/3/23